InFocus Capital Partners Completes Series A Round for Qura, Maker of Implantable IOP Monitor

February 2, 2018: By Jon Swedien

InFocus Capital Partners announced Jan. 31 that it has provided a Series A round of funding for Qura Inc., developer of the QSmart, a wireless implantable pressure sensor technology and monitoring system for glaucoma.

New York-based InFocus did not say how much money was raised.

The venture capital fund specializes in the identification, capitalization, and development of breakthrough and disruptive opportunities in ophthalmology.

The QSmart is a micro-sized wireless implantable pressure sensor that can be programmed to a physician’s specifications to monitor and collect the most relevant data concerning IOP changes, InFocus said. Information captured by the QSmart is delivered to a hand-held device or tablet, allowing physicians to evaluate the effectiveness of current glaucoma treatment for their patients in real-time, InFocus said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility